<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="c7f7ab90-badd-446a-beac-af1d455cb751"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>These highlights do not include all the information needed to use BROMFENAC OPHTHALMIC SOLUTION 0.07% safely and effectively. <br/>See full prescribing information for BROMFENAC OPHTHALMIC SOLUTION. <br/>BROMFENAC ophthalmic solution 0.07% <br/>Initial U.S. Approval: 1997</title>
   <effectiveTime value="20250305"/>
   <setId root="26f3e5b3-a739-4b09-8046-e71ecb3a5a7b"/>
   <versionNumber value="5"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id extension="089153071" root="1.3.6.1.4.1.519.1"/>
            <name>Lupin Pharmaceuticals, Inc.</name>
            <assignedEntity>
               <assignedOrganization>
                  <id extension="675923163" root="1.3.6.1.4.1.519.1"/>
                  <name>LUPIN LIMITED</name>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="863645527" root="1.3.6.1.4.1.519.1"/>
                        <name>LUPIN LIMITED</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C43360" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MANUFACTURE"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="68180-433" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84731" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="PACK"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="68180-433" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
               </assignedOrganization>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="1d3b9b67-4470-4f4e-be7c-354465ab29e3"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL Product Data Elements Section"/>
               <effectiveTime value="20250305"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="68180-433" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>bromfenac sodium</name>
                        <formCode code="C60992" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="SOLUTION/ DROPS"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>bromfenac sodium</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIM">
                           <quantity>
                              <numerator value="0.805" unit="mg"/>
                              <denominator value="1" unit="mL"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="8ECV571Y37" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>BROMFENAC SODIUM</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="864P0921DW" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>BROMFENAC</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="F5UM2KM3W7" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>BENZALKONIUM CHLORIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="R57ZHV85D4" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>BORIC ACID</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="7FLD91C86K" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>EDETATE DISODIUM</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="FZ989GH94E" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POVIDONE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="91MBZ8H3QO" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM BORATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="55X04QC32I" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM HYDROXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="VTK01UQK3G" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM SULFITE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="Y27PUL9H56" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TYLOXAPOL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="059QF0KO0R" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>WATER</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="3" unit="mL"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43171" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE, DROPPER"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="1" unit="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="68180-433-02" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20240108"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C102835" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 2: Prefilled Drug Delivery Device/System (syringe, patch, etc.)" xsi:type="CE"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA206027" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20240108"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38287" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="OPHTHALMIC"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="ID63">
               <id root="71242104-be4a-40d8-84d9-687d8a120b48"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>1 INDICATIONS AND USAGE</title>
               <effectiveTime value="20240315"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph ID="ID67">Bromfenac ophthalmic solution is a nonsteroidal anti-inflammatory drug (NSAID) indicated for the treatment of postoperative inflammation and reduction of ocular pain in patients who have undergone cataract surgery. (<linkHtml href="#ID63">1</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID64">
                     <id root="2d7cd5c9-8d00-457d-b1c2-7eae482f0de9"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph ID="ID65">Bromfenac ophthalmic solution, 0.07% is indicated for the treatment of postoperative inflammation and reduction of ocular pain in patients who have undergone cataract surgery.</paragraph>
                     </text>
                     <effectiveTime value="20240315"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID68">
               <id root="b550eaa0-d258-4078-88b4-7883394d9411"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>2 DOSAGE AND ADMINISTRATION</title>
               <effectiveTime value="20151209"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph ID="ID74">Instill one drop into the affected eye once daily beginning 1 day prior to surgery, continued on the day of surgery, and through the first 14 days post-surgery. (<linkHtml href="#ID70">2.1</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID69">
                     <id root="68a94a30-99b6-4dcf-ab2b-3646c50c580d"/>
                     <title>2.1 Recommended Dosing</title>
                     <text>
                        <paragraph ID="ID70">One drop of bromfenac ophthalmic solution should be applied to the affected eye once daily beginning 1 day prior to cataract surgery, continued on the day of surgery, and through the first 14 days of the postoperative period. </paragraph>
                     </text>
                     <effectiveTime value="20151209"/>
                  </section>
               </component>
               <component>
                  <section ID="ID71">
                     <id root="99e47355-e2ee-4c59-bb8b-f78e6061a7de"/>
                     <title>2.2 Use with Other Topical Ophthalmic Medications</title>
                     <text>
                        <paragraph ID="ID72">Bromfenac ophthalmic solution may be administered in conjunction with other topical ophthalmic medications such as alpha-agonists, beta-blockers, carbonic anhydrase inhibitors, cycloplegics, and mydriatics. Drops should be administered at least 5 minutes apart. </paragraph>
                     </text>
                     <effectiveTime value="20151209"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID75">
               <id root="28588d6f-7450-4e09-b936-4f457470dfc8"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>3 DOSAGE FORMS AND STRENGTHS</title>
               <effectiveTime value="20151209"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph ID="ID79">Topical ophthalmic solution: bromfenac 0.07 % (<linkHtml href="#ID75">3</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID76">
                     <id root="88bca911-1ede-4cfa-af64-873e86473d0b"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph ID="ID77">Topical ophthalmic solution: bromfenac 0.07 % </paragraph>
                     </text>
                     <effectiveTime value="20151209"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID80">
               <id root="b1f8c083-1099-466a-bdbc-382c91737b15"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>4 CONTRAINDICATIONS</title>
               <effectiveTime value="20151209"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph ID="ID84">None (<linkHtml href="#ID80">4</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID81">
                     <id root="d8e5e075-86ff-438b-a6d5-82304c2749e3"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph ID="ID82">None </paragraph>
                     </text>
                     <effectiveTime value="20151209"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID85">
               <id root="89dbd434-ab70-4702-8392-bf65339f9dd5"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>5 WARNINGS AND PRECAUTIONS</title>
               <effectiveTime value="20151209"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" ID="ID99" styleCode="Disc">
                           <item>  Sulfite Allergic Reactions <content styleCode="bold">(</content>
                              <linkHtml href="#ID86">5.1</linkHtml>
                              <content styleCode="bold">) </content>
                           </item>
                           <item>  Slow or Delayed Healing <content styleCode="bold">(</content>
                              <linkHtml href="#ID88">5.2</linkHtml>
                              <content styleCode="bold">) </content>
                           </item>
                           <item>  Potential for cross-sensitivity <content styleCode="bold">(</content>
                              <linkHtml href="#ID90">5.3</linkHtml>
                              <content styleCode="bold">) </content>
                           </item>
                           <item>  Increase bleeding of ocular tissues <content styleCode="bold">(</content>
                              <linkHtml href="#ID92">5.4</linkHtml>
                              <content styleCode="bold">) </content>
                           </item>
                           <item>  Corneal effects including keratitis <content styleCode="bold">(</content>
                              <linkHtml href="#ID94">5.5</linkHtml>
                              <content styleCode="bold">) </content>
                           </item>
                           <item>  Contact Lens Wear <content styleCode="bold">(</content>
                              <linkHtml href="#ID96">5.6</linkHtml>
                              <content styleCode="bold">) </content>
                           </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID86">
                     <id root="29469aea-599b-4e16-97de-c27b24f24f7e"/>
                     <title>5.1 Sulfite Allergic Reactions</title>
                     <text>
                        <paragraph ID="ID87">Contains sodium sulfite, a sulfite that may cause allergic type reactions including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in certain susceptible people. The overall prevalence of sulfite sensitivity in the general population is unknown and probably low. Sulfite sensitivity is seen more frequently in asthmatic than in non-asthmatic people. </paragraph>
                     </text>
                     <effectiveTime value="20151209"/>
                  </section>
               </component>
               <component>
                  <section ID="ID88">
                     <id root="b2ce3651-e73b-48bd-9ea9-13c976c73ccb"/>
                     <title>5.2 Slow or Delayed Healing</title>
                     <text>
                        <paragraph ID="ID89">All topical nonsteroidal anti-inflammatory drugs (NSAIDs), including bromfenac, may slow or delay healing. Topical corticosteroids are also known to slow or delay healing. Concomitant use of topical NSAIDs and topical steroids may increase the potential for healing problems. </paragraph>
                     </text>
                     <effectiveTime value="20151209"/>
                  </section>
               </component>
               <component>
                  <section ID="ID90">
                     <id root="e1f8780e-f1ba-4337-8385-28897e301165"/>
                     <title>5.3 Potential for Cross-Sensitivity</title>
                     <text>
                        <paragraph ID="ID91">There is the potential for cross-sensitivity to acetylsalicylic acid, phenylacetic acid derivatives, and other NSAIDs, including bromfenac. Therefore, caution should be used when treating individuals who have previously exhibited sensitivities to these drugs. </paragraph>
                     </text>
                     <effectiveTime value="20151209"/>
                  </section>
               </component>
               <component>
                  <section ID="ID92">
                     <id root="d64ade7f-cd9e-4d73-8423-37f7e01ddcb0"/>
                     <title>5.4 Increased Bleeding Time</title>
                     <text>
                        <paragraph ID="ID93">With some NSAIDs, including bromfenac, there exists the potential for increased bleeding time due to interference with platelet aggregation. There have been reports that ocularly applied NSAIDs may cause increased bleeding of ocular tissues (including hyphemas) in conjunction with ocular surgery. </paragraph>
                        <paragraph>It is recommended that bromfenac ophthalmic solution be used with caution in patients with known bleeding tendencies or who are receiving other medications which may prolong bleeding time. </paragraph>
                     </text>
                     <effectiveTime value="20151209"/>
                  </section>
               </component>
               <component>
                  <section ID="ID94">
                     <id root="17fb888e-ce25-4a1f-b351-02bb49bcd7c7"/>
                     <title>5.5 Keratitis and Corneal Reactions</title>
                     <text>
                        <paragraph ID="ID95">Use of topical NSAIDs may result in keratitis. In some susceptible patients, continued use of topical NSAIDs may result in epithelial breakdown, corneal thinning, corneal erosion, corneal ulceration or corneal perforation. These events may be sight threatening. Patients with evidence of corneal epithelial breakdown should immediately discontinue use of topical NSAIDs, including bromfenac, and should be closely monitored for corneal health. </paragraph>
                        <paragraph>Post-marketing experience with topical NSAIDs suggests that patients with complicated ocular surgeries, corneal denervation, corneal epithelial defects, diabetes mellitus, ocular surface diseases (e.g., dry eye syndrome), rheumatoid arthritis, or repeat ocular surgeries within a short period of time may be at increased risk for corneal adverse events which may become sight threatening. Topical NSAIDs should be used with caution in these patients. </paragraph>
                        <paragraph>Post-marketing experience with topical NSAIDs also suggests that use more than 24 hours prior to surgery or use beyond 14 days post-surgery may increase patient risk for the occurrence and severity of corneal adverse events. </paragraph>
                     </text>
                     <effectiveTime value="20151209"/>
                  </section>
               </component>
               <component>
                  <section ID="ID96">
                     <id root="ba750304-6e80-42cd-b2c1-7aebd311a6bf"/>
                     <title>5.6 Contact Lens Wear</title>
                     <text>
                        <paragraph ID="ID97">Bromfenac ophthalmic solution should not be instilled while wearing contact lenses. Remove contact lenses prior to instillation of bromfenac ophthalmic solution. The preservative in bromfenac ophthalmic solution, benzalkonium chloride may be absorbed by soft contact lenses. Lenses may be reinserted after 10 minutes following administration of bromfenac ophthalmic solution. </paragraph>
                     </text>
                     <effectiveTime value="20151209"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID100">
               <id root="18cc564d-ea26-4851-9d80-0b6856ac2bea"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>6 ADVERSE REACTIONS</title>
               <effectiveTime value="20151209"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph ID="ID104">The most commonly reported adverse reactions in 3 to 8 % of patients were anterior chamber inflammation, foreign body sensation, eye pain, photophobia, and vision blurred. <content styleCode="bold">(</content>
                           <linkHtml href="#ID102">6.1</linkHtml>
                           <content styleCode="bold">)</content>. </paragraph>
                        <paragraph>
                           <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact Lupin Pharmaceuticals, Inc. at 1-800-399-2561 or FDA at 1-800-FDA-1088 or <content styleCode="underline">
                                 <linkHtml href="#ID">www.fda.gov/medwatch</linkHtml>
                              </content>
                           </content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID101">
                     <id root="8c98a5f1-7839-4771-9661-52e7522be548"/>
                     <title>6.1 Clinical Trial Experience</title>
                     <text>
                        <paragraph ID="ID102">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice. </paragraph>
                        <paragraph>The most commonly reported adverse reactions following use of bromfenac ophthalmic solution following cataract surgery include: anterior chamber inflammation, foreign body sensation, eye pain, photophobia, and vision blurred. These reactions were reported in 3 to 8 % of patients. </paragraph>
                     </text>
                     <effectiveTime value="20151209"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID105">
               <id root="3159cc7a-b3c7-4b36-a252-42f479c1512d"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>8 USE IN SPECIFIC POPULATIONS</title>
               <effectiveTime value="20151209"/>
               <component>
                  <section ID="ID106">
                     <id root="a3083304-a45e-4f1a-b5f9-6737e853c0da"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>8.1 Pregnancy</title>
                     <text>
                        <paragraph ID="ID107">Treatment of rats at oral doses up to 0.9 mg/kg/day (systemic exposure 90 times the systemic exposure predicted from the recommended human ophthalmic dose [RHOD] assuming the human systemic concentration is at the limit of quantification) and rabbits at oral doses up to 7.5 mg/kg/day (150 times the predicted human systemic exposure) produced no treatment-related malformations in reproduction studies. However, embryo-fetal lethality and maternal toxicity were produced in rats and rabbits at 0.9 mg/kg/day and 7.5 mg/kg/day, respectively. In rats, bromfenac treatment caused delayed parturition at 0.3 mg/kg/day (30 times the predicted human exposure), and caused dystocia, increased neonatal mortality and reduced postnatal growth at 0.9 mg/kg/day<content styleCode="italics">. </content>
                        </paragraph>
                        <paragraph>There are no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. </paragraph>
                        <paragraph>Because of the known effects of prostaglandin biosynthesis-inhibiting drugs on the fetal cardiovascular system (closure of ductus arteriosus), the use of bromfenac ophthalmic solution during late pregnancy should be avoided. </paragraph>
                     </text>
                     <effectiveTime value="20151209"/>
                  </section>
               </component>
               <component>
                  <section ID="ID108">
                     <id root="5e118a13-67ed-408f-b480-aec8a72146a9"/>
                     <code code="34080-2" codeSystem="2.16.840.1.113883.6.1" displayName="NURSING MOTHERS SECTION"/>
                     <title>8.3 Nursing Mothers</title>
                     <text>
                        <paragraph ID="ID109">Caution should be exercised when bromfenac ophthalmic solution is administered to a nursing woman. </paragraph>
                     </text>
                     <effectiveTime value="20151209"/>
                  </section>
               </component>
               <component>
                  <section ID="ID110">
                     <id root="c97ca62a-327d-40cb-8b3d-e160b5625e45"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>8.4 Pediatric Use</title>
                     <text>
                        <paragraph ID="ID111">Safety and efficacy in pediatric patients below the age of 18 years have not been established. </paragraph>
                     </text>
                     <effectiveTime value="20151209"/>
                  </section>
               </component>
               <component>
                  <section ID="ID112">
                     <id root="f665e512-46ec-45cb-a06a-3c3a8eb50824"/>
                     <code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION"/>
                     <title>8.5 Geriatric Use</title>
                     <text>
                        <paragraph ID="ID113">There is no evidence that the efficacy or safety profiles for bromfenac ophthalmic solution differ in patients 70 years of age and older compared to younger adult patients. </paragraph>
                     </text>
                     <effectiveTime value="20151209"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID114">
               <id root="edfca9c1-d522-4301-b6e8-9dc3545d236b"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>11 DESCRIPTION</title>
               <text>
                  <paragraph ID="ID115">Bromfenac ophthalmic solution 0.07 % is a sterile, topical, nonsteroidal anti-inflammatory drug (NSAID) for ophthalmic use. Each mL of bromfenac ophthalmic solution contains 0.805 mg bromfenac sodium sesquihydrate (equivalent to 0.7 mg bromfenac free acid). The USAN name for bromfenac sodium sesquihydrate is bromfenac sodium. Bromfenac sodium is designated chemically as sodium [2-amino-3-(4-bromobenzoyl) phenyl] acetate sesquihydrate, with an molecular formula of C<sub>15</sub>H<sub>11</sub>BrNNaO<sub>3</sub>• 1<sub>½</sub>H<sub>2</sub>O. The chemical structure for bromfenac sodium sesquihydrate is: </paragraph>
                  <renderMultiMedia referencedObject="MM1"/>
                  <paragraph ID="ID117">Bromfenac sodium is a yellow to orange crystalline powder. The molecular weight of bromfenac sodium is 383.17. Bromfenac ophthalmic solution, 0.07 % is supplied as a sterile aqueous 0.07 % solution, with a pH of 7.55 to 8.15. The osmolality of bromfenac ophthalmic solution, 0.07 % is approximately 280 to 340 mOsmol/kg. </paragraph>
                  <paragraph>
                     <content styleCode="bold">Each mL of bromfenac ophthalmic solution, 0.07 % contains: </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Active</content>: Each mL contains bromfenac sodium sesquihydrate 0.0805 %, which is equivalent to bromfenac free acid 0.07 %. </paragraph>
                  <paragraph>
                     <content styleCode="bold">Preservative</content>: benzalkonium chloride 0.005 % </paragraph>
                  <paragraph>
                     <content styleCode="bold">Inactives</content>: boric acid, edetate disodium (dihydrate), povidone, sodium borate, sodium sulfite, sodium hydroxide to adjust pH, tyloxapol and water for injection USP. </paragraph>
               </text>
               <effectiveTime value="20250305"/>
               <component>
                  <observationMedia ID="MM1">
                     <text>Fig-1</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="c7f7ab90-badd-446a-beac-af1d455cb751-01.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID118">
               <id root="c0413836-0ba1-44e0-8d48-18ad0cdc400f"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>12 CLINICAL PHARMACOLOGY</title>
               <effectiveTime value="20151209"/>
               <component>
                  <section ID="ID119">
                     <id root="98a221d6-2e2d-4a0d-9f96-9a3051b8edcd"/>
                     <code code="43679-0" codeSystem="2.16.840.1.113883.6.1" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>12.1 Mechanism of Action</title>
                     <text>
                        <paragraph ID="ID120">Bromfenac is a nonsteroidal anti-inflammatory drug (NSAID) that has anti-inflammatory activity. The mechanism of its action is thought to be due to its ability to block prostaglandin synthesis by inhibiting cyclooxygenase (COX) 1 and 2. Prostaglandins have been shown in many animal models to be mediators of certain kinds of intraocular inflammation. In studies performed in animal eyes, prostaglandins have been shown to produce disruption of the blood-aqueous humor barrier, vasodilation, increased vascular permeability, leukocytosis, and increased intraocular pressure. </paragraph>
                     </text>
                     <effectiveTime value="20151209"/>
                  </section>
               </component>
               <component>
                  <section ID="ID121">
                     <id root="970a67ad-2f33-469e-b62b-38a204d8278c"/>
                     <code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/>
                     <title>12.3 Pharmacokinetics</title>
                     <text>
                        <paragraph ID="ID122">The plasma concentration of bromfenac following ocular administration of 0.07 % bromfenac ophthalmic solution in humans is unknown. Based on the maximum proposed dose of one drop to each eye (0.035 mg) and PK information from other routes of administration, the systemic concentration of bromfenac is estimated to be below the limit of quantification (50 ng/mL) at steady-state in humans. </paragraph>
                     </text>
                     <effectiveTime value="20151209"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID123">
               <id root="5b558e7a-62a0-463b-9ecd-8298efe0794c"/>
               <code code="43680-8" codeSystem="2.16.840.1.113883.6.1" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>13 NONCLINICAL TOXICOLOGY</title>
               <effectiveTime value="20151209"/>
               <component>
                  <section ID="ID124">
                     <id root="7785ffe8-2773-423d-bfdd-3b5e57ddc1ac"/>
                     <title>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</title>
                     <text>
                        <paragraph ID="ID125">Long-term carcinogenicity studies in rats and mice given oral doses of bromfenac up to 0.6 mg/kg/day (systemic exposure 30 times the systemic exposure predicted from the recommended human ophthalmic dose [RHOD] assuming the human systemic concentration is at the limit of quantification) and 5 mg/kg/day (340 times the predicted human systemic exposure), respectively, revealed no significant increases in tumor incidence. </paragraph>
                        <paragraph>Bromfenac did not show mutagenic potential in various mutagenicity studies, including the reverse mutation, chromosomal aberration, and micronucleus tests. </paragraph>
                        <paragraph>Bromfenac did not impair fertility when administered orally to male and female rats at doses up to 0.9 mg/kg/day and 0.3 mg/kg/day, respectively (systemic exposure 90 and 30 times the predicted human exposure, respectively). </paragraph>
                     </text>
                     <effectiveTime value="20151209"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID126">
               <id root="fff50183-decc-47a6-84d3-86f981ac0c1f"/>
               <code code="34092-7" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL STUDIES SECTION"/>
               <title>14 CLINICAL STUDIES</title>
               <effectiveTime value="20231123"/>
               <component>
                  <section ID="ID127">
                     <id root="aac536ca-5dba-411a-8274-49b751b8f38e"/>
                     <title>14.1 Ocular Inflammation and Pain</title>
                     <text>
                        <paragraph ID="ID128">Bromfenac 0.07 % QD for the treatment of postoperative inflammation and reduction of ocular pain was evaluated in two multi-center, randomized, double-masked, parallel-group and placebo (vehicle)-controlled studies. Patients undergoing cataract surgery self-administered bromfenac 0.07 % or vehicle once daily, beginning 1 day prior to surgery, continuing on the morning of surgery and for 14 days after surgery. Complete clearance of ocular inflammation (0 cell and no flare) was assessed on Days 1, 3, 8 and 15 post-surgery using slit lamp biomicroscopy. The pain score was self-reported. The primary efficacy endpoint was the proportion of subjects who had complete clearance of ocular inflammation by day 15. In the intent-to-treat analyses from both assessments, complete clearance at Day 8 and Day 15, bromfenac 0.07 % was superior to vehicle as shown in the following table.</paragraph>
                        <table ID="ID129" width="100%" styleCode="Noautorules">
                           <col width="37%"/>
                           <col width="15%"/>
                           <col width="16%"/>
                           <col width="12%"/>
                           <col width="17%"/>
                           <tbody>
                              <tr>
                                 <td colspan="5" valign="top" styleCode="Lrule Toprule Botrule Rrule" align="left"> Proportion of Subjects with Cleared Ocular Inflammation (0 cells and no flare)<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode=" Lrule Botrule Rrule" align="left"> Study <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left"> Visit <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left"> Bromfenac 0.07 % <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left"> Vehicle <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left"> Difference (%) (Asymptotic 95 % CI)<br/>  <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode=" Lrule Rrule" align="left"> Study 1 <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left"> At Day 8 <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left"> 27/112 (24.1%) <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left"> 7/108 (6.5%) <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left"> 17.6 (8.4, 26.8) <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Lrule Botrule Rrule"/>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left"> At Day 15 <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left"> 51/112 (45.5%) <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left"> 14/108 (13.0%) <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left"> 32.5 (21.4, 43.8) <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode=" Lrule Rrule" align="left"> Study 2 <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left"> At Day 8 <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left"> 33/110 (30.0%) <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left"> 14/110 (12.7%) <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left"> 17.3 (6.7, 27.9) <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Lrule Botrule Rrule"/>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left"> At Day 15 <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left"> 50/110 (45.5%) <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left"> 30/110 (27.3%) <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left"> 18.2 (5.7, 30.7) <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="5" valign="top" styleCode="Lrule Botrule Rrule" align="left"> Proportion of Subjects who Were Pain Free<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode=" Lrule Botrule Rrule" align="left"> Study <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left"> Visit <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left"> Bromfenac 0.07% <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left"> Vehicle <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left"> Difference (%) (Asymptotic 95% CI) <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode=" Lrule Botrule Rrule" align="left"> Study 1 <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left"> At Day 1 <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left"> 91/112 (81.3%) <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left"> 47/108 (43.5%) <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left"> 37.7 (25.9, 49.6) <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode=" Lrule Botrule Rrule" align="left"> Study 2 <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left"> At Day 1 <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left"> 84/110 (76.4%) <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left"> 61/110 (55.5%) <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left"> 20.9 (8.7, 33.1) <br/>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                     <effectiveTime value="20231123"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID130">
               <id root="c0496256-fe04-4c60-9123-d271d60af74a"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>16 HOW SUPPLIED/STORAGE AND HANDLING</title>
               <text>
                  <paragraph ID="ID131">Bromfenac Ophthalmic Solution, 0.07% is supplied in a white low density polyethylene bottle fitted with a white low density polyethylene nozzle and sealed with grey colored high density polyethylene cap with tamper-evident ring as follows:</paragraph>
                  <list listType="unordered" ID="ID132" styleCode="Disc">
                     <item>1.6 mL in 5 mL      bottle (NDC 68180-433-01)</item>
                     <item>3      mL in a 5 mL bottle (NDC 68180-433-02) </item>
                  </list>
                  <paragraph ID="ID133">
                     <content styleCode="bold">Storage </content>
                  </paragraph>
                  <paragraph>Store at 25°C (77°F); excursions permitted to 15 to 30°C (59 to 86°F) [See USP Controlled Room Temperature].</paragraph>
               </text>
               <effectiveTime value="20231130"/>
            </section>
         </component>
         <component>
            <section ID="ID134">
               <id root="54f9a79f-522c-4590-9a64-9415b5fc3c70"/>
               <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>17 PATIENT COUNSELING INFORMATION</title>
               <effectiveTime value="20250305"/>
               <component>
                  <section ID="ID136">
                     <id root="a9afab25-f5e2-438a-9ec6-81f516ffe0ac"/>
                     <title>17.1 Slowed or Delayed Healing</title>
                     <text>
                        <paragraph ID="ID142">Advise patients of the possibility that slow or delayed healing may occur while using NSAIDs. </paragraph>
                     </text>
                     <effectiveTime value="20151209"/>
                  </section>
               </component>
               <component>
                  <section ID="ID137">
                     <id root="800de0c1-fe64-412e-9eb4-0855b5ea2adc"/>
                     <title>17.2 Sterility of Dropper Tip</title>
                     <text>
                        <paragraph ID="ID143">Advise patients to replace bottle cap after using and to not touch dropper tip to any surface, as this may contaminate the contents. </paragraph>
                        <paragraph>Advise patients that a single bottle of bromfenac ophthalmic solution be used to treat only one eye. </paragraph>
                     </text>
                     <effectiveTime value="20151209"/>
                  </section>
               </component>
               <component>
                  <section ID="ID140">
                     <id root="d6b28ed3-360d-44fd-be01-f5c384b5b154"/>
                     <title>17.3 Concomitant Use of Contact Lenses</title>
                     <text>
                        <paragraph ID="ID144">Advise patients to remove contact lenses prior to instillation of bromfenac ophthalmic solution. The preservative in bromfenac ophthalmic solution, benzalkonium chloride, may be absorbed by soft contact lenses. Lenses may be reinserted after 10 minutes following administration of bromfenac ophthalmic solution. </paragraph>
                     </text>
                     <effectiveTime value="20151209"/>
                  </section>
               </component>
               <component>
                  <section ID="ID141">
                     <id root="56a7cf99-d85f-42ae-b5f1-587216f09863"/>
                     <title>17.4 Concomitant Topical Ocular Therapy</title>
                     <text>
                        <paragraph ID="ID145">If more than one topical ophthalmic medication is being used, the medicines should be administered at least 5 minutes apart. </paragraph>
                        <paragraph>LUPIN and the <renderMultiMedia referencedObject="IMGID1451"/> are registered trademarks of Lupin Pharmaceuticals, Inc.</paragraph>
                     </text>
                     <effectiveTime value="20250305"/>
                  </section>
               </component>
               <component>
                  <observationMedia ID="IMGID1451">
                     <text>Image</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="c7f7ab90-badd-446a-beac-af1d455cb751-145-1.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID155">
               <id root="5d1621af-8ad1-477e-b66e-9fcc0f8b6d49"/>
               <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
               <text>
                  <paragraph ID="ID154">Manufactured for:</paragraph>
                  <paragraph>
                     <content styleCode="bold">Lupin Pharmaceuticals, Inc.</content>
                  </paragraph>
                  <paragraph>Naples, FL 34108</paragraph>
                  <paragraph>United States</paragraph>
                  <paragraph>Manufactured by:</paragraph>
                  <paragraph>
                     <content styleCode="bold">Lupin Limited</content>
                  </paragraph>
                  <paragraph>Pithampur (M.P.) – 454 775</paragraph>
                  <paragraph>India</paragraph>
                  <paragraph>Revised: November 2024                                                             ID: 277248</paragraph>
               </text>
               <effectiveTime value="20250305"/>
            </section>
         </component>
         <component>
            <section ID="ID146">
               <id root="95f2263b-cf21-4377-a7fa-f5bfc000d31b"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PACKAGE LABEL.PRINCIPAL DISPLAY PANEL</title>
               <text>
                  <paragraph ID="ID150">Bromfenac Ophthalmic Solution, 0.07 %</paragraph>
                  <paragraph>3.0 mL in 5 mL bottle (NDC 68180-433-02)</paragraph>
                  <paragraph>Rx Only</paragraph>
                  <paragraph>Carton and Container Labels</paragraph>
                  <renderMultiMedia referencedObject="MM2"/>
                  <renderMultiMedia referencedObject="MM3"/>
               </text>
               <effectiveTime value="20250305"/>
               <component>
                  <observationMedia ID="MM2">
                     <text>Carton Label-NDC 68180-433-02</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="c7f7ab90-badd-446a-beac-af1d455cb751-02.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM3">
                     <text>Container Label-NDC 68180-433-02</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="c7f7ab90-badd-446a-beac-af1d455cb751-03.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>